Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 7, 2006

View Archived Issues

Anthocyanin derivative may have potential application in cardiovascular disease

Novel antimalarial targeting plasmapepsin II reported

Pharmacological profile of novel ACAT inhibitor reported by Kyoto

MDX-1100's potential in ulcerative colitis described

BXL-628 has relevant molecular effects in experimental autoimmune prostatitis

CPU-057 shows benefit in a rat model of pulmonary hypertension

AstraZeneca inlicenses Cubicin rights for China and other countries

New phase II trial investigates fenretinide in geographic atrophy

Alexza completes transaction to fund development of AZ-002 and AZ-004

Sangamo to acquire Edwards Lifesciences' angiogenesis program

Acadia to license complementary intellectual property for serotonin platform

AVI BioPharma awarded biodefense contract by Defense Threat Reduction Agency

Cypher Select Plus launched in Canada

Caprospinol clinical trials for Alzheimer's to begin early next year

Lion bioscience shareholders approve name change to Sygnis Pharma

ARYS-01 cream shows activity in patients with primary herpes zoster episodes

FM-VP4 is dose responsive with clinically significant reduction in LDL-cholesterol

New E.U. approval for Hycamtin with chemotherapy for cervical cancer

SMP-986 improves voiding efficiency in anesthetized dogs

Recent patents describe new treatment options for endocrine-related disorders

Novel treatment options for obesity reported in recent Novo Nordisk and Takeda patents

Highest doses of XR-NTX demonstrate opioid blockade for 28 days

Phase IIa trial investigates SC-12267 for rheumatoid arthritis

Avexa and TargetDrug sign binding sheet for CCR5 HIV drug program

Amgen responds to reports on use and safety of Epogen and Aranesp

Curaxin CBLC-102 studied in phase II for hormone-refractory prostate cancer

Phase III program under way for oral contraceptive NOMAC/E2

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...